Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp lowered its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 9.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,213 shares of the company’s stock after selling 2,883 shares during the quarter. Mackenzie Financial Corp’s holdings in Hims & Hers Health were worth $775,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. LPL Financial LLC grew its stake in Hims & Hers Health by 1.0% during the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company’s stock valued at $2,369,000 after purchasing an additional 980 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in Hims & Hers Health by 26.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 23,129 shares of the company’s stock valued at $559,000 after purchasing an additional 4,898 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at approximately $208,000. National Bank of Canada FI grew its stake in Hims & Hers Health by 438.7% during the 4th quarter. National Bank of Canada FI now owns 2,990 shares of the company’s stock valued at $72,000 after purchasing an additional 2,435 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Hims & Hers Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company’s stock valued at $104,724,000 after purchasing an additional 40,447 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $47.70, for a total value of $552,413.70. Following the sale, the chief financial officer owned 54,084 shares of the company’s stock, valued at approximately $2,579,806.80. This trade represents a 17.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,572 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $58.70, for a total value of $150,976.40. Following the completion of the sale, the insider directly owned 155,593 shares in the company, valued at approximately $9,133,309.10. This trade represents a 1.63% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 737,704 shares of company stock worth $40,644,035. Company insiders own 13.71% of the company’s stock.

Hims & Hers Health Trading Down 7.6%

Shares of NYSE HIMS opened at $51.30 on Thursday. The company has a market cap of $11.48 billion, a price-to-earnings ratio of 64.12, a price-to-earnings-growth ratio of 2.06 and a beta of 2.08. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 1.32 and a debt-to-equity ratio of 1.72. The stock’s 50 day simple moving average is $53.79 and its 200 day simple moving average is $44.63.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The company’s revenue for the quarter was up 72.6% on a year-over-year basis. During the same period last year, the business posted $0.06 EPS. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. UBS Group set a $30.00 price objective on Hims & Hers Health in a research note on Monday, June 23rd. Morgan Stanley reiterated an “equal weight” rating and issued a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Bank of America lifted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research report on Tuesday, April 29th. Truist Financial lifted their target price on Hims & Hers Health from $45.00 to $48.00 and gave the stock a “hold” rating in a research report on Thursday, July 17th. Finally, TD Cowen lowered Hims & Hers Health from a “buy” rating to a “hold” rating and decreased their target price for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $39.83.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.